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e appreciate the interest of Dr. Torabi and colleagues in our
tudy (1), which demonstrated the significance of heart failure
HF) after myocardial infarction.
They identified the significance of early HF in900 patients in
similar time period (1998), followed up for a similar time
5 years). Heart failure not only develops as an early event, but as
mportantly shown by our analysis, it also develops in those who
eft the hospital without HF, with 71% developing late HF within
years. The median age of our 7,733-patient Alberta cohort (1) is
years older than that of Dr. Torabi and colleagues, which may
xplain in part the morbidity and mortality event rates.
Late development of HF is well established by landmark trials
f angiotensin-converting enzyme inhibitors, indicating that pre-
ention of late remodeling and the subsequent attenuation of HF
s a key efficacy signal of these agents (2). Dr. Torabi and
olleagues used a unique definition of HF, including HF signs or
ymptoms in patients on a diuretic agent or who died shortly after
eveloping major cardiac dysfunction, for example, cardiogenic
hock or pulmonary edema. Both warrant exploration in other
atasets to ensure their external validity; the coding of HF by our
ethod has undergone validation in multiple jurisdictions (3,4).
The authors assert that death is not a single entity, and we
gree; hence, we did not classify cause of death. Given the
omplexity of HF, adjudication by a clinical events committee
sing rigorous and published methodology, as shown in a recent
linical trial in patients with high-risk ST-segment elevationyocardial infarction (5), is a key strategy to facilitate inclusion of
F as an end point. In this trial (6) and others, development of
F at 90 days occupies a key position in the primary composite
nd point.
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